Iantrek Announces 1-Year Clinical Results of Its Bio-Interventional Technology for Uveoscleral Outflow Enhancement in Open-Angle Glaucoma Patients WHITE PLAINS, N.Y., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Iantrek, Inc., a venture-backed medical technology company pioneering next-generation bio- and micro-interventional approaches for ophthalmic...

Iantrek Announces Publication of Results of its Bio-interventional Uveoscleral Outflow Technology in Patients with Open-Angle Glaucoma WHITE PLAINS, N.Y., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Iantrek, Inc., a venture-backed, medical technology company pioneering next-generation bio- and micro-interventional approaches for the...

Iantrek reports two upcoming American Academy of Ophthalmology presentations of its breakthrough glaucoma surgical technologies, including 1-year results of a novel supraciliary outflow micro-interventional procedure Biotech startup to present 12 month data for novel Glaucoma treatment at AAO.

12-month clinical results of a novel micro-interventional bio-stenting procedure published in the British Journal of Ophthalmology WHITE PLAINS, N.Y., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Iantrek today announced the publication of 12-month clinical results of a novel bio-stenting procedure using the company’s microsurgical...

Iantrek Raises $23M Series B Financing to Advance Next Generation Ophthalmic Micro-Interventional Technologies WHITE PLAINS, N.Y., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Iantrek, Inc., a medical device company founded by ophthalmic innovator Dr. Sean Ianchulev, announced the closing of a $23M Series B financing....